Search

Displaying results 311 - 320 of 10000 in total
  1. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). … In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873].

    Categories: Nonergot-derivative Dopamine Receptor AgonistsProducts: MIPEXOBEX TM 1.0 MG, MIPEXOBEX TM 0.25 MG
  2. Pathway

    Ziconotide NMDA and Substance P Receptor Pain Inhibition Action Pathway

    smpdb.ca/view/SMP0126347
    Drug action

    Ziconotide, also known as SNX-111, is an N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and sy...

    Drugs: Glutamic acid · Calcium · Sar9, Met (O2)11-Substance P · Ziconotide
    Enzymes: Substance-P receptor, Glutamate [NMDA] receptor subunit 3B
  3. Drug

    Mirvetuximab

    go.drugbank.com/drugs/DB16235
    Investigational

    Synonyms: Immunoglobulin g1, anti-(human folate receptor .alpha.) (human-mus musculus monoclonal m9346a heavy chain), disulfide with human-mus musculus monoclonal m9346a light chain, dimer
  4. Drug

    Lonigutamab

    go.drugbank.com/drugs/DB18940
    Investigational

    Lonigutamab is under investigation in clinical trial NCT05683496 (Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)).

    Synonyms: Immunoglobulin g1 (de-c-terminal-lysine), anti-(human insulin-like growth factor i receptor) (human-mus musculus monoclonal hz208f2-4 .gamma.1-chain), disulfide with human-mus musculus monoclonal hz208f2, Immunoglobulin g1-kappa, anti-(homo sapiens igf1r (insulin like growth factor 1 receptor, igf1-r, igf-1r, cd221)), humanized monoclonal antibody
  5. Drug

    Doxycycline

    go.drugbank.com/drugs/DB00254
    ApprovedInvestigationalVet approved

    [A174034] Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.[A251730]

    Products: Doxy 100(tm) Doxycycline, DOXYCYCLIN AL 100 T
  6. Drug

    KITE-222

    go.drugbank.com/drugs/DB17195
    Investigational

    Synonyms: An autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1)
  7. Drug

    Pabinafusp alfa

    go.drugbank.com/drugs/DB15633
    Investigational

    Pabinafusp alfa is under investigation in clinical trial NCT03568175 (A Study of JR-141 in Patients With Mucopolysaccharidosis II).

    Synonyms: Immunoglobulin G1-kappa, anti-(human transferrin receptor 1, tfr1) humanized monoclonal antibody, fused with human iduronate-2-sulfatase, glycoform alfa:, IMMUNOGLOBULIN G1, ANTI-(HUMAN TRANSFERRIN RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JR-141 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN IDURONATE
  8. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    Approved

    Docusate acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass [L1801]. Docusate can be orally or rectally administered. … However the effectiveness of docusate in treating constipation remains unclear, as several studies report docusate to be no more effective than placebo for increasing the frequency of stool or stool softening

    Mixtures: Tl-hem 150, TL-SelectProducts: H E B Stool Softener laxative, Sirop Docusate De Sodium USP 20mg/5ml
  9. Drug

    Unoprostone

    go.drugbank.com/drugs/DB06826
    ApprovedWithdrawn

    Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate. The main indication of Unoprostane is treatment of glucoma.

  10. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366].

    Categories: NMDA Receptor Antagonists, N-methyl-D-aspartate Receptor Antagonist